Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR-SB Utilizing Semi-Mechanistic Model. — Lecanemab is a humanized IgG1 monoclonal antibody binding with high affinity to protofibrils of amyloid-beta (Aβ) protein. In clinical studies, lecanemab...

Evidence span

Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR-SB Utilizing Semi-Mechanistic Model. — Lecanemab is a humanized IgG1 monoclonal antibody binding with high affinity to protofibrils of amyloid-beta (Aβ) protein. In clinical studies, lecanemab...

From Bhagunde P et al. 2026, CPT: pharmacometrics & systems pharmacology

Method & conditions

Evidence type

experimental

Method

manual state transition; control details require source inspection

Species

Homo sapiens

Conditions

Brain; Humans; Alzheimer Disease; Disease Progression; Positron-Emission Tomography — CPT: pharmacometrics & systems pharmacology 2026

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required